Соединенные Штаты - английский - NLM (National Library of Medicine)

sagent pharmaceuticals - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml

Соединенные Штаты - английский - NLM (National Library of Medicine)

onco therapies limited - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml

Соединенные Штаты - английский - NLM (National Library of Medicine)

bluepoint laboratories - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors ( see clinical studies: breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months

Соединенные Штаты - английский - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included

Соединенные Штаты - английский - NLM (National Library of Medicine)

alembic pharmaceuticals limited - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included

Австралия - английский - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: primary treatment of ovarian cancer in combination with a platinum agent.; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: * primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy. * adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. * treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - paclitaxel 6 mg/ml;   - concentrate for infusion - 6 mg/ml - active: paclitaxel 6 mg/ml   excipient: ethanol polyoxyl 35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic ovarian cancer after failure of standard therapy.